Sign in Subscribe
Cancer

Reprogramming the Body's Immune System: UCLA Researchers Pioneer New Cancer Treatment

Strategic Insights

— 1 min read

UCLA scientists have made a groundbreaking discovery in cancer treatment, successfully reprogramming a patient's blood-forming stem cells to generate a continuous supply of functional T cells, the immune system's most powerful cancer-killing agents. This approach offers a new way to deliver immunotherapy, providing a longer-lasting defense against cancer. Led by physician-scientist Dr. Theodore Scott Nowicki, the research aims to address the limitations of current cancer immunotherapies, which often work at first but eventually die off or become exhausted.

Key Takeaways:

  • The UCLA team has developed a novel strategy for treating hard-to-treat cancers, including solid tumors, by combining engineered T cells with genetically modified stem cells.
  • The approach involves engineering a patient's own stem cells to continually produce fresh, cancer-fighting T cells, offering a much longer-lasting defense against the disease.
  • The scientists targeted a specific cancer marker called NY-ESO-1, which is rarely seen in healthy adult tissues, making it a relatively safe target for the T cells to recognize and attack.
  • The study showed promising results, with one patient showing signs of tumor regression and detectable levels of the new immune cells for months.
  • The therapy involves stem cell collection, gene modification, and high-dose chemotherapy, which require time, expertise, and a strong patient, making it still experimental and not without risk.
  • The research holds potential for fighting diseases other than cancer, such as infections like HIV or autoimmune diseases.

Statistics:

  • 80% of synovial sarcomas have the NY-ESO-1 tumor marker.
  • 30 dedicated academic investigators were involved in the study.
  • The research took over a decade to bring to patients.
  • The study was funded by the California Institute for Regenerative Medicine (CIRM), the National Institutes of Health (NIH), Hyundai Hope on Wheels, the Tower Cancer Research Foundation, the Parker Institute for Cancer Immunotherapy, and the Ressler Family Fund.
  • The UCLA team, led by Dr. Nowicki and Dr. Antoni Ribas, included members from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center.

Sources:

  • "UCLA Scientists Reprogram Patient's Stem Cells to Fight Cancer," VerticalNews, August 2025.
  • "Pilot study demonstrated the feasibility of genetically programming blood stem cells to become cancer-targeting immune cells," Nature Communications, August 2025.

Read more